STAY INFORMED. VISIT NHIA.ORG/COVID19 FOR INFORMATION AND RESOURCES ABOUT CORONAVIRUS DISEASE (COVID-19).
For the past several months, America’s consumer markets have been plagued by supply chain issues. Unfortunately, medical supplies are not immune to these challenges. NHIA is aware that many members are experiencing shortages of administration sets for ambulatory infusion pumps.
This shortage can directly impact patient care, thus the association is working with manufacturers and suppliers to get more information about when these issues might be resolved and if they can offer alternatives (view statement from Smiths Medical).
In the meantime, we want to remind providers that the decision to use an infusion pump—and which pump to use—is a clinical one. In order to assist in assessing patient needs and considering alternatives, NHIA has developed a few recommendations for managing current shortages, including considerations for selecting an appropriate infusion device.
NHIA submitted comments pointing out the advantages of home-based administration of subcutaneous Ig (SCIG) for chronic inflammatory demyelinating polyneuropathy (CIPD).
NHIA submitted comments on a CMS proposed rule (CMS-1770-P) that would affect Medicare payments and coverage of COVID-19 vaccines and monoclonal antibodies (mAbs) and coding and billing requirements related to the use of single dose containers and drug waste.
As part of a strategic focus on promoting health equity, The National Home Infusion Foundation (NHIF) recently adopted standardized categories for race and ethnicity data collection and is encouraging all providers to include voluntary questions to capture this data. NHIF will utilize this data throughout its projects to evaluate equitable access to infusion treatments in alternate sites.
© 2022, National Home Infusion Association
All Rights Reserved by NHIA
